Literature DB >> 20658475

Variation in innate immunity genes and risk of multiple myeloma.

Mark P Purdue1, Qing Lan, Idan Menashe, Tongzhang Zheng, Yawei Zhang, Meredith Yeager, H Dean Hosgood, Shelia H Zahm, Stephen J Chanock, Nathaniel Rothman, Dalsu Baris.   

Abstract

Multiple myeloma (MM) is a B-cell lymphoid malignancy suspected to be associated with immunologic factors. Given recent findings associating single-nucleotide polymorphisms (SNPs) in innate immunity genes with non-Hodgkin lymphoma, we conducted an investigation of innate immune gene variants using specimens from a population-based case-control study of MM conducted in Connecticut women. Tag SNPs (N = 1461) summarizing common variation in 149 gene regions were genotyped in non-Hispanic Caucasian subjects (103 cases, 475 controls). Odds ratios (OR) and 95% confidence intervals (CI) relating SNP associations with MM were computed using unconditional logistic regression, while the MinP test was used to investigate associations with MM at the gene level. We calculated permutation-adjusted P-values and false discovery rates (FDR) to account for the number of comparisons performed in SNP-level and gene-level tests, respectively. Three genes were associated with MM when controlling for a FDR of ≤10%: SERPINE1 (P(MinP)  < 0.0001; FDR = 0.02), CCR7 (P(MinP)  = 0.0006; FDR = 0.06) and HGF (P(MinP)  = 0.001; FDR = 0.08). Two SNPs demonstrated robust associations: SERPINE1 rs2227667 (P = 2.1 × 10(-5) , P(permutation)  = 0.03) and HGF rs17501108 (P = 5.0 × 10(-5) , P(permutation)  = 0.07). Our findings suggest that genetic variants in SERPINE1 and HGF, and possibly CCR7, are associated with MM risk, and warrant further investigation in other studies.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20658475      PMCID: PMC2980579          DOI: 10.1002/hon.954

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  45 in total

1.  Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk.

Authors:  A Nieters; L Beckmann; E Deeg; N Becker
Journal:  Genes Immun       Date:  2006-09-14       Impact factor: 2.676

2.  Common genetic variants associated with plasma fibrin D-dimer concentration in older European- and African-American adults.

Authors:  L A Lange; A P Reiner; C L Carty; N S Jenny; M Cushman; E M Lange
Journal:  J Thromb Haemost       Date:  2008-01-17       Impact factor: 5.824

3.  Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.

Authors:  J Kodama; T Kusumoto; N Seki; T Matsuo; Y Ojima; K Nakamura; A Hongo; Y Hiramatsu
Journal:  Ann Oncol       Date:  2006-10-10       Impact factor: 32.976

4.  HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Authors:  Therese Standal; Niels Abildgaard; Unn-Merete Fagerli; Berit Stordal; Oyvind Hjertner; Magne Borset; Anders Sundan
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

5.  Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women.

Authors:  Ola Landgren; Yawei Zhang; Sheila Hoar Zahm; Peter Inskip; Tongzhang Zheng; Dalsu Baris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11-28       Impact factor: 4.254

6.  Common variants in genes that mediate immunity and risk of multiple myeloma.

Authors:  Elizabeth E Brown; Qing Lan; Tongzhang Zheng; Yawei Zhang; Sophia S Wang; Shelia Hoar-Zahm; Stephen J Chanock; Nathaniel Rothman; Dalsu Baris
Journal:  Int J Cancer       Date:  2007-06-15       Impact factor: 7.396

7.  Population genomics of human gene expression.

Authors:  Barbara E Stranger; Alexandra C Nica; Matthew S Forrest; Antigone Dimas; Christine P Bird; Claude Beazley; Catherine E Ingle; Mark Dunning; Paul Flicek; Daphne Koller; Stephen Montgomery; Simon Tavaré; Panos Deloukas; Emmanouil T Dermitzakis
Journal:  Nat Genet       Date:  2007-09-16       Impact factor: 38.330

8.  Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study.

Authors:  P E Morange; N Saut; M C Alessi; J S Yudkin; M Margaglione; G Di Minno; A Hamsten; S E Humphries; D A Tregouet; I Juhan-Vague
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-26       Impact factor: 8.311

9.  Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.

Authors:  Livio Trentin; Marta Miorin; Monica Facco; Ilenia Baesso; Samuela Carraro; Anna Cabrelle; Nilla Maschio; Michela Bortoli; Gianni Binotto; Francesco Piazza; Fausto Adami; Renato Zambello; Carlo Agostini; Gianpietro Semenzato
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

10.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

View more
  9 in total

1.  Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation.

Authors:  Christina A Clarke; Sally L Glaser; Scarlett L Gomez; Sophia S Wang; Theresa H Keegan; Juan Yang; Ellen T Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

Review 2.  Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.

Authors:  Alexandra J Greenberg; S Vincent Rajkumar; Celine M Vachon
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

Review 3.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

4.  Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Authors:  Leah H Schinasi; Elizabeth E Brown; Nicola J Camp; Sophia S Wang; Jonathan N Hofmann; Brian C Chiu; Lucia Miligi; Laura E Beane Freeman; Silvia de Sanjose; Leslie Bernstein; Alain Monnereau; Jacqueline Clavel; Guido J Tricot; Djordje Atanackovic; Pierluigi Cocco; Laurent Orsi; James A Dosman; John R McLaughlin; Mark P Purdue; Wendy Cozen; John J Spinelli; Anneclaire J de Roos
Journal:  Br J Haematol       Date:  2016-06-22       Impact factor: 6.998

5.  Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.

Authors:  Kevin D Boyd; Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Zoe J Konn; William J Tapper; Brian A Walker; Christopher P Wardell; Walter M Gregory; Alex J Szubert; Faith E Davies; Gareth J Morgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-15       Impact factor: 4.254

6.  Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study.

Authors:  Lacreis R Kidd; Dominique Z Jones; Erica N Rogers; Nayla C Kidd; Sydney Beache; James E Rudd; Camille Ragin; Maria Jackson; Norma McFarlane-Anderson; Marshall Tulloch-Reid; Seian Morrison; Guy N Brock; Shirish S Barve; Kevin S Kimbro
Journal:  Hered Cancer Clin Pract       Date:  2012-11-20       Impact factor: 2.857

7.  Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma.

Authors:  Anneclaire J De Roos; John Spinelli; Elizabeth B Brown; Djordje Atanackovic; Dalsu Baris; Leslie Bernstein; Parveen Bhatti; Nicola J Camp; Brian C Chiu; Jacqueline Clavel; Wendy Cozen; Silvia De Sanjosé; James A Dosman; Jonathan N Hofmann; John R McLaughlin; Lucia Miligi; Alain Monnereau; Laurent Orsi; Mark P Purdue; Leah H Schinasi; Guido J Tricot; Sophia S Wang; Yawei Zhang; Brenda M Birmann; Pierluigi Cocco
Journal:  Occup Environ Med       Date:  2018-08-18       Impact factor: 4.948

Review 8.  Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Clin Dev Immunol       Date:  2012-04-11

9.  PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.

Authors:  Jiaxi Wang; Yuanyuan Peng; Hejia Guo; Cuiping Li
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.